Desferrioxamine in chronic progressive Multiple Sclerosis: a pilot study
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Chronic progressive Multiple Sclerosis is refractory to many conventional treatments. We performed a pilot study testing desferoxamine (DFO) as a candidate in the treatment of chronic progressive Multiple Sclerosis. DFO was given daily by 8 h subcutaneous infusions at a dose of 2 grams daily for 7 days, followed by 1 gram daily for 7 days. Eighteen of 19 individuals completed the full dose of 21 grams. One patient was unable to complete the course due to nausea. No acute deterioration of neurological status was seen during the administration of DFO. No worsening of vision or hearing was noted except that the one patient who was unable to tolerate the medication had a transient reduction in hearing. All patients had a local redness at the injection site. None of the patients had any sudden worsening during or shortly after the treatment This pilot study suggests that DFO is relatively well tolerated by Multiple Sclerosis patients when given in a short course of therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oxygen free radicals and iron in relation to biology and medicine: Some problems and concepts
Halliwell, B., & Gutteridge, J. M. C. (1986) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(86)90305-x · Cited by 2,038
Intramuscular desferrioxamine in patients with Alzheimer's disease
MCLACHLAN, D. (1991) · The Lancet · doi:10.1016/0140-6736(91)92978-b · Cited by 764
Inhibition of autoimmune neuropathological process by treatment with an iron-chelating agent.
Bowern, N., Ramshaw, I. A., Clark, I. A., & Doherty, P. C. (1984) · The Journal of experimental medicine · doi:10.1084/jem.160.5.1532 · Cited by 119
Brock, J. H., & Ng, J. (1983) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.1983.tb00164.x · Cited by 57
Comparative Study of Different Iron-Chelating Agents in Cold-Induced Brain Edema
Ikeda, Y., Ikeda, K., & Long, D. M. (1989) · Neurosurgery · doi:10.1227/00006123-198906000-00006 · Cited by 38
Cited by
Progressive multiple sclerosis: from pathophysiology to therapeutic strategies
Faissner, S., Plemel, J. R., Gold, R., & Yong, V. W. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0035-2 · Cited by 459
Targeting iron metabolism in drug discovery and delivery
Crielaard, B. J., Lammers, T., & Rivella, S. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.248 · Cited by 352
Smouldering multiple sclerosis: the ‘real MS’
Giovannoni, G., Popescu, V., Wuerfel, J., Hellwig, K., Iacobaeus, E., Jensen, M. B., García-Domínguez, J. M., Sousa, L., De Rossi, N., Hupperts, R., et al. (2022) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864211066751 · Cited by 271
Serum ferritin, transferrin and soluble transferrin receptor levels in multiple sclerosis patients
Sfagos, C., Makis, A. C., Chaidos, A., Hatzimichael, E. C., Dalamaga, A., Kosma, K., & Bourantas, K. L. (2005) · Multiple Sclerosis Journal · doi:10.1191/1352458505ms1171oa · Cited by 84
Iron chelation and multiple sclerosis
Weigel, K. J., Lynch, S. G., & LeVine, S. M. (2014) · ASN NEURO · doi:10.1042/an20130037 · Cited by 63
“A second deferoxamine trial examined 19 patients with MS as defined by the criteria by Poser et al. (1983) together with an abnormal MRI and a reduction of the EDSS of 0.5 over the previous 2 years (Lynch et al., 1996).”
BackgroundMethodInfluentialSelf-citation
Metadata
- Authors
- Lynch, S. G., Peters, K., & LeVine, S. M.
- Venue
- Multiple Sclerosis Journal
- Publisher
- SAGE Publications
- Published
- 1996-10
- Volume
- 2
- Issue
- 3
- Pages
- 157-160
- ISSN
- 1352-4585 (ISSN-L)
- 1477-0970
- OpenAlex
- W1592937389
- Cited by
- 33
- References
- 5
- FWCI
- 0.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Desferrioxamine in chronic progressive Multiple Sclerosis: a pilot study. https://app.cochat.ai/papers/10.1177/135245859600200306
- The paper
- Lynch, S. G., Peters, K., & LeVine, S. M. (1996). Desferrioxamine in chronic progressive Multiple Sclerosis: a pilot study. Multiple Sclerosis Journal. https://doi.org/10.1177/135245859600200306
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.